Anna E. Martinez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anna E. Martinez has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Gabriela Petrof
Dermatology Department, Great Ormond Street Hospital NHS Foundation Trust, London, UK
4 shared publications- Gabriela Petrof
Great Ormond Street Hospital NHS Foundation Trust, London, UK
4 shared publications - Kate Hutchence
Clinical Trials Research Unit, Sheffield Centre for Health and Related Research (SCHARR), School of Medicine and Population Health, The University of Sheffield, Sheffield, UK
3 shared publications - Maria Laura Bageta
Department of Dermatology Great Ormond Street Hospital NHS Foundation Trust London UK
3 shared publications - Pablo Lopez Balboa
Dermatology Department Great Ormond Street Hospital for Children NHS Trust London UK
3 shared publications - Christine Prodinger
Department of Dermatology and Allergology University Hospital of the Paracelsus Medical University Salzburg Austria
2 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (9) , 237
Eliciting health state utilities for open wounds in dystrophic epidermolysis bullosa
- 23 July 2026
- Published by Springer Nature in Quality of Life Research
- Vol. 35 (9) , 237
Open AccessEliciting health state utilities for open wounds in dystrophic epidermolysis bullosa
- Open Access
- 3 June 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial
Background: Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic skin condition causing fragile skin, blistering, and scarring. It leads to chronic pain, slow wound healing, and severe limitations, profoundly impacting patient and family quality of life. Umbilical cord tissue-derived mesenchymal stromal cells (UC-MSC) have shown therapeutic promise. The Mission EB trial (ISRCTN14409785; registration date 25/03/2021) assessed UC-MSC safety and effectiveness in children with RDEB in a placebo-controlled, double-blinded, crossover study. Methods: This study used a qualitative research design with semi-structured interviews and thematic analysis, to explore Mission EB trial treatment impact on the quality of life of patients and parents. Parents and patients were interviewed at two time points (approximately 3- and 12-months post-randomisation). Purposive sampling included 10 parents and 6 children; 13 individuals (8 adults, 5 children) were interviewed twice (once in each study period). Interviews were transcribed verbatim, independently coded, with overall impressions agreed upon prior to unblinding. Results: RDEB significantly impacted daily life, marked by pain and itch. Participants were hopeful of the trial, willing to pursue minor improvements. UC-MSC infusions led to reduced pain/itchiness, improved wound healing, and resulted in fewer self-reported dressing changes. These benefits often translated to increased energy, improved eating, and greater daily activity participation. Benefits were more pronounced with active treatment. Negative effects were minimal, primarily venous access difficulties. Blinded participants could discern active UC-MSC from placebo based on symptom changes; 10 of 13 showed clear differences aligning with treatment. All parents interviewed expressed willingness for their child to receive treatment again. Conclusions: This qualitative research provides valuable insights into perceived benefits of UC-MSC treatment for children with RDEB. Interview findings regarding symptom improvement and participants’ ability to discern active treatment shed light on its perceived benefit in RDEB, especially in milder RDEB patients. The study highlights the critical importance of qualitative methodologies in adding to quantitative trial outcomes and capturing the meaningful impact of interventions on the lives of patients and families particularly where quantitative measures may not fully reflect lived experience.
- 3 June 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessMesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with Recessive Dystrophic Epidermolysis Bullosa (MissionEB): a qualitative sub study of a randomised, double-blind, placebo controlled, crossover, phase 3 trial
Background: Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a rare genetic skin condition causing fragile skin, blistering, and scarring. It leads to chronic pain, slow wound healing, and severe limitations, profoundly impacting patient and family quality of life. Umbilical cord tissue-derived mesenchymal stromal cells (UC-MSC) have shown therapeutic promise. The Mission EB trial (ISRCTN14409785; registration date 25/03/2021) assessed UC-MSC safety and effectiveness in children with RDEB in a placebo-controlled, double-blinded, crossover study. Methods: This study used a qualitative research design with semi-structured interviews and thematic analysis, to explore Mission EB trial treatment impact on the quality of life of patients and parents. Parents and patients were interviewed at two time points (approximately 3- and 12-months post-randomisation). Purposive sampling included 10 parents and 6 children; 13 individuals (8 adults, 5 children) were interviewed twice (once in each study period). Interviews were transcribed verbatim, independently coded, with overall impressions agreed upon prior to unblinding. Results: RDEB significantly impacted daily life, marked by pain and itch. Participants were hopeful of the trial, willing to pursue minor improvements. UC-MSC infusions led to reduced pain/itchiness, improved wound healing, and resulted in fewer self-reported dressing changes. These benefits often translated to increased energy, improved eating, and greater daily activity participation. Benefits were more pronounced with active treatment. Negative effects were minimal, primarily venous access difficulties. Blinded participants could discern active UC-MSC from placebo based on symptom changes; 10 of 13 showed clear differences aligning with treatment. All parents interviewed expressed willingness for their child to receive treatment again. Conclusions: This qualitative research provides valuable insights into perceived benefits of UC-MSC treatment for children with RDEB. Interview findings regarding symptom improvement and participants’ ability to discern active treatment shed light on its perceived benefit in RDEB, especially in milder RDEB patients. The study highlights the critical importance of qualitative methodologies in adding to quantitative trial outcomes and capturing the meaningful impact of interventions on the lives of patients and families particularly where quantitative measures may not fully reflect lived experience.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 3311322
Real‐World Insights on Birch Triterpenes in the Treatment of Inherited Epidermolysis Bullosa: Translating Experience to Practice
Epidermolysis bullosa (EB) comprises a heterogeneous group of rare genetic disorders characterized by skin and mucosal fragility, leading to recurrent blistering, chronic wounds, and significant morbidity. Recent advances have led to the approval of several EB‐specific wound treatments, allowing patients, caregivers, and healthcare practitioners a broader arsenal to improve disease management and outcomes. This includes birch triterpenes (also known as birch bark extract or Oleogel‐S10), a topical gel containing 10% birch triterpene extract combined with sunflower oil. Here, we consolidate the real‐world clinical experience from 12 EB specialists who treated over 140 patients with birch triterpenes in centers across Europe and the USA. Experience in patients treated with birch triterpenes spans both pediatric and adult populations diagnosed with junctional EB and dominant/recessive dystrophic EB, and with both acute and chronic wounds. The authors address patient‐ and wound‐specific considerations, treatment application, removal, and duration, as well as integration with other treatments. The authors, in addition, provide actionable guidance for optimizing treatment regimens, managing patient and caregiver expectations, and addressing challenges related to real‐world use of birch triterpenes. The importance of patient education and treatment adherence, as well as assessing functional outcomes, such as pain reduction, improved mobility, and quality of life measures in the evaluation of treatment effectiveness, are also discussed. This review seeks to contextualize the evidence derived from clinical trials with the realities of routine clinical practice, equipping healthcare practitioners to provide care that is both evidence‐based and attuned to the unique needs of individuals living with EB.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 3311322
Open AccessReal‐World Insights on Birch Triterpenes in the Treatment of Inherited Epidermolysis Bullosa: Translating Experience to Practice
Epidermolysis bullosa (EB) comprises a heterogeneous group of rare genetic disorders characterized by skin and mucosal fragility, leading to recurrent blistering, chronic wounds, and significant morbidity. Recent advances have led to the approval of several EB‐specific wound treatments, allowing patients, caregivers, and healthcare practitioners a broader arsenal to improve disease management and outcomes. This includes birch triterpenes (also known as birch bark extract or Oleogel‐S10), a topical gel containing 10% birch triterpene extract combined with sunflower oil. Here, we consolidate the real‐world clinical experience from 12 EB specialists who treated over 140 patients with birch triterpenes in centers across Europe and the USA. Experience in patients treated with birch triterpenes spans both pediatric and adult populations diagnosed with junctional EB and dominant/recessive dystrophic EB, and with both acute and chronic wounds. The authors address patient‐ and wound‐specific considerations, treatment application, removal, and duration, as well as integration with other treatments. The authors, in addition, provide actionable guidance for optimizing treatment regimens, managing patient and caregiver expectations, and addressing challenges related to real‐world use of birch triterpenes. The importance of patient education and treatment adherence, as well as assessing functional outcomes, such as pain reduction, improved mobility, and quality of life measures in the evaluation of treatment effectiveness, are also discussed. This review seeks to contextualize the evidence derived from clinical trials with the realities of routine clinical practice, equipping healthcare practitioners to provide care that is both evidence‐based and attuned to the unique needs of individuals living with EB.
- Open Access
- 15 August 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 88, 103417
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase
- 15 August 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 88, 103417
Open AccessMesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase
- Open Access
Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extension
Introduction: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic mucocutaneous fragility disorder characterised by chronic blistering, slow wound healing and increased risk of squamous cell carcinoma. Current management options are very limited. Methods: This is a randomised (1:1), placebo-controlled, double-blinded crossover (A/B) trial with an internal phase I dose de-escalation (4+5 design) in the first 3 months and a 12-month continued treatment follow-on open-label study if 3-month outcome data from the crossover trial indicate safe and beneficial effects. RDEB is a rare condition, so we expect to recruit a maximum of 36 participants based on feasibility and not formal power considerations. Participants aged>6 months and 6 cells/kg intravenous infusion of umbilical cord-derived mesenchymal stem cells or placebo at the start of each crossover period (day 0) and 14 days later. The dose will be de-escalated to 1–1.5×10 6 cells/kg depending on observed toxicity. For the main crossover trial, the primary outcome is the change in disease severity as measured by the Epidermolysis Bullosa Disease Activity and Scarring Index at 3 months from day 0 infusion. Secondary outcomes measured at 3 and 6 months from day 0 infusion include changes in general clinical appearance of skin disease, pain and itch, and quality of life. Adverse events and serious adverse events will be monitored throughout the trial. Ethics and dissemination: North East—York Research Ethics Committee approved the protocol (ref: 21/NE/0016) on 16 March 2021. Findings will be published in peer-reviewed scientific journals, presented at relevant national and international conferences, and an open-access final report submitted to the funder. Trial registration number: ISRCTN14409785 . Protocol V. 8.0, 14 November 2022.
Open AccessMesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extension
Introduction: Recessive dystrophic epidermolysis bullosa (RDEB) is a severe genetic mucocutaneous fragility disorder characterised by chronic blistering, slow wound healing and increased risk of squamous cell carcinoma. Current management options are very limited. Methods: This is a randomised (1:1), placebo-controlled, double-blinded crossover (A/B) trial with an internal phase I dose de-escalation (4+5 design) in the first 3 months and a 12-month continued treatment follow-on open-label study if 3-month outcome data from the crossover trial indicate safe and beneficial effects. RDEB is a rare condition, so we expect to recruit a maximum of 36 participants based on feasibility and not formal power considerations. Participants aged>6 months and 6 cells/kg intravenous infusion of umbilical cord-derived mesenchymal stem cells or placebo at the start of each crossover period (day 0) and 14 days later. The dose will be de-escalated to 1–1.5×10 6 cells/kg depending on observed toxicity. For the main crossover trial, the primary outcome is the change in disease severity as measured by the Epidermolysis Bullosa Disease Activity and Scarring Index at 3 months from day 0 infusion. Secondary outcomes measured at 3 and 6 months from day 0 infusion include changes in general clinical appearance of skin disease, pain and itch, and quality of life. Adverse events and serious adverse events will be monitored throughout the trial. Ethics and dissemination: North East—York Research Ethics Committee approved the protocol (ref: 21/NE/0016) on 16 March 2021. Findings will be published in peer-reviewed scientific journals, presented at relevant national and international conferences, and an open-access final report submitted to the funder. Trial registration number: ISRCTN14409785 . Protocol V. 8.0, 14 November 2022.
- Open Access
- 20 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (3) , 394-404
Management of oesophageal strictures in inherited epidermolysis bullosa: a clinical practice guideline
Inherited epidermolysis bullosa (EB) is a group of rare and complex genetic disorders characterized by fragility of the skin and mucous membranes. Specifically, the gastrointestinal tract is commonly involved with a range of complications, one of the most disabling being oesophageal strictures (OS). OS manifest with progressive dysphagia, which in turn contributes to malnutrition, chronic anaemia and growth delay, with high impact on the quality of life of patients and their families. DEBRA International has supported the development of clinical practice guidelines (CPGs) for different aspects of EB care. The present CPG aims to provide healthcare professionals and affected individuals and their caregivers with recommendations on diagnostic procedures, preventive measures and treatment of OS. An international multidisciplinary panel comprising clinical experts and patient and public involvement (PPI) representatives developed the CPG, following an international PPI survey and literature review. The GRADE methodology was adopted to define PICO (population, intervention, comparison, outcome) questions, implement a literature appraisal process and prepare recommendations. Three recommendations are focused on OS diagnosis, and seven on preventive nonpharmacological (diet, oral care and therapeutic education) and pharmacological measures (topical corticosteroids) and treatment procedures. Treatment focuses particularly on oesophageal dilatation and how to delay and manage disease relapses. It is expected that this CPG will contribute to improving the quality and equity of care for individuals affected with EB, and will hopefully foster clinical research to increase evidence, in particular on noninvasive OS treatment to prevent complications and delay relapses.
- 20 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (3) , 394-404
Open AccessManagement of oesophageal strictures in inherited epidermolysis bullosa: a clinical practice guideline
Inherited epidermolysis bullosa (EB) is a group of rare and complex genetic disorders characterized by fragility of the skin and mucous membranes. Specifically, the gastrointestinal tract is commonly involved with a range of complications, one of the most disabling being oesophageal strictures (OS). OS manifest with progressive dysphagia, which in turn contributes to malnutrition, chronic anaemia and growth delay, with high impact on the quality of life of patients and their families. DEBRA International has supported the development of clinical practice guidelines (CPGs) for different aspects of EB care. The present CPG aims to provide healthcare professionals and affected individuals and their caregivers with recommendations on diagnostic procedures, preventive measures and treatment of OS. An international multidisciplinary panel comprising clinical experts and patient and public involvement (PPI) representatives developed the CPG, following an international PPI survey and literature review. The GRADE methodology was adopted to define PICO (population, intervention, comparison, outcome) questions, implement a literature appraisal process and prepare recommendations. Three recommendations are focused on OS diagnosis, and seven on preventive nonpharmacological (diet, oral care and therapeutic education) and pharmacological measures (topical corticosteroids) and treatment procedures. Treatment focuses particularly on oesophageal dilatation and how to delay and manage disease relapses. It is expected that this CPG will contribute to improving the quality and equity of care for individuals affected with EB, and will hopefully foster clinical research to increase evidence, in particular on noninvasive OS treatment to prevent complications and delay relapses.
- Open Access
- 22 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (22)
Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating, and life-threatening inherited skin fragility disorder that comes about due to a lack of functional type VII collagen, for which no effective therapy exists. ABCB5 + dermal mesenchymal stem cells (ABCB5 + MSCs) possess immunomodulatory, inflammation-dampening, and tissue-healing capacities. In a Col7a1 –/– mouse model of RDEB, treatment with ABCB5 + MSCs markedly extended the animals’ lifespans. METHODS: In this international, multicentric, single-arm, phase I/IIa clinical trial, 16 patients (aged 4–36 years) enrolled into 4 age cohorts received 3 i.v. infusions of 2 × 10 6 ABCB5 + MSCs/kg on days 0, 17, and 35. Patients were followed up for 12 weeks regarding efficacy and 12 months regarding safety. RESULTS: At 12 weeks, statistically significant median (IQR) reductions in the Epidermolysis Bullosa Disease Activity and Scarring Index activity (EBDASI activity) score of 13.0% (2.9%–30%; P = 0.049) and the Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa clinician (iscorEB‑c) score of 18.2% (1.9%–39.8%; P = 0.037) were observed. Reductions in itch and pain numerical rating scale scores were greatest on day 35, amounting to 37.5% (0.0%–42.9%; P = 0.033) and 25.0% (–8.4% to 46.4%; P = 0.168), respectively. Three adverse events were considered related to the cell product: 1 mild lymphadenopathy and 2 hypersensitivity reactions. The latter 2 were serious but resolved without sequelae shortly after withdrawal of treatment. CONCLUSION: This trial demonstrates good tolerability, manageable safety, and potential efficacy of i.v. ABCB5 + MSCs as a readily available disease-modifying therapy for RDEB and provides a rationale for further clinical evaluation. TRIAL REGISTRATION: Clinicaltrials.gov NCT03529877; EudraCT 2018-001009-98. FUNDING: The trial was sponsored by RHEACELL GmbH & Co. KG. Contributions by NYF and MHF to this work were supported by the NIH/National Eye Institute (NEI) grants RO1EY025794 and R24EY028767.
- 22 November 2021
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 6 (22)
Open AccessClinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa
BACKGROUND: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare, devastating, and life-threatening inherited skin fragility disorder that comes about due to a lack of functional type VII collagen, for which no effective therapy exists. ABCB5 + dermal mesenchymal stem cells (ABCB5 + MSCs) possess immunomodulatory, inflammation-dampening, and tissue-healing capacities. In a Col7a1 –/– mouse model of RDEB, treatment with ABCB5 + MSCs markedly extended the animals’ lifespans. METHODS: In this international, multicentric, single-arm, phase I/IIa clinical trial, 16 patients (aged 4–36 years) enrolled into 4 age cohorts received 3 i.v. infusions of 2 × 10 6 ABCB5 + MSCs/kg on days 0, 17, and 35. Patients were followed up for 12 weeks regarding efficacy and 12 months regarding safety. RESULTS: At 12 weeks, statistically significant median (IQR) reductions in the Epidermolysis Bullosa Disease Activity and Scarring Index activity (EBDASI activity) score of 13.0% (2.9%–30%; P = 0.049) and the Instrument for Scoring Clinical Outcome of Research for Epidermolysis Bullosa clinician (iscorEB‑c) score of 18.2% (1.9%–39.8%; P = 0.037) were observed. Reductions in itch and pain numerical rating scale scores were greatest on day 35, amounting to 37.5% (0.0%–42.9%; P = 0.033) and 25.0% (–8.4% to 46.4%; P = 0.168), respectively. Three adverse events were considered related to the cell product: 1 mild lymphadenopathy and 2 hypersensitivity reactions. The latter 2 were serious but resolved without sequelae shortly after withdrawal of treatment. CONCLUSION: This trial demonstrates good tolerability, manageable safety, and potential efficacy of i.v. ABCB5 + MSCs as a readily available disease-modifying therapy for RDEB and provides a rationale for further clinical evaluation. TRIAL REGISTRATION: Clinicaltrials.gov NCT03529877; EudraCT 2018-001009-98. FUNDING: The trial was sponsored by RHEACELL GmbH & Co. KG. Contributions by NYF and MHF to this work were supported by the NIH/National Eye Institute (NEI) grants RO1EY025794 and R24EY028767.
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1094-1101
The natural history of laryngo‐onycho‐cutaneous syndrome: A case series of six pediatric patients and literature review
Background/Objectives: Laryngo‐onycho‐cutaneous syndrome (LOC) is a rare subtype of junctional epidermolysis bullosa (JEB), featuring aberrant granulation tissue formation in the skin, larynx, and eyes. So far, three mutations including the specific (founder) mutation in exon 39 of LAMA3 (c.151dup) have been identified, but sparse data exists regarding the natural history, the genotype‐phenotype correlation, and its differentiation from other JEB types.Methods: We reviewed our pediatric EB database to identify English children with clinical and genetically diagnosed LOC within the last 15 years. Their demographic, clinical, and laboratory data were examined. We searched three databases for case reports of LOC between January 1986 and November 2020 and extracted clinical and molecular details.Results: We identified 6 LOC patients, all female (mean age 5.4 years). Periungual hypergranulation and skin fragility were the earliest presenting signs (0‐3 months), followed by laryngeal stenosis, symblepharon (mean onset 10.7 and 11.8 months, respectively), and dental abnormalities. Five children developed anemia at an average of 19.2 months. We identified 22 published studies in English with 31 cases.Conclusions: This study delineates the disease course of LOC and highlights the overlap with some forms of JEB. Classical signs/symptoms including anemia appear early in life. Genetic analysis revealed three new LOC‐associated variants and underscores the finding that interpretation of skin immunolabeling and molecular diagnostics can be challenging. We provide recommendations on management of this complex syndrome.
- 13 September 2021
- Published by Wiley in Pediatric Dermatology
- Vol. 38 (5) , 1094-1101
The natural history of laryngo‐onycho‐cutaneous syndrome: A case series of six pediatric patients and literature review
Background/Objectives: Laryngo‐onycho‐cutaneous syndrome (LOC) is a rare subtype of junctional epidermolysis bullosa (JEB), featuring aberrant granulation tissue formation in the skin, larynx, and eyes. So far, three mutations including the specific (founder) mutation in exon 39 of LAMA3 (c.151dup) have been identified, but sparse data exists regarding the natural history, the genotype‐phenotype correlation, and its differentiation from other JEB types.Methods: We reviewed our pediatric EB database to identify English children with clinical and genetically diagnosed LOC within the last 15 years. Their demographic, clinical, and laboratory data were examined. We searched three databases for case reports of LOC between January 1986 and November 2020 and extracted clinical and molecular details.Results: We identified 6 LOC patients, all female (mean age 5.4 years). Periungual hypergranulation and skin fragility were the earliest presenting signs (0‐3 months), followed by laryngeal stenosis, symblepharon (mean onset 10.7 and 11.8 months, respectively), and dental abnormalities. Five children developed anemia at an average of 19.2 months. We identified 22 published studies in English with 31 cases.Conclusions: This study delineates the disease course of LOC and highlights the overlap with some forms of JEB. Classical signs/symptoms including anemia appear early in life. Genetic analysis revealed three new LOC‐associated variants and underscores the finding that interpretation of skin immunolabeling and molecular diagnostics can be challenging. We provide recommendations on management of this complex syndrome.
- 26 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (1) , 223-225
Infantile haemangioma presenting in combination with a cerebriform naevus sebaceous on the scalp
- 26 June 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 47 (1) , 223-225
Infantile haemangioma presenting in combination with a cerebriform naevus sebaceous on the scalp
- Open Access
- 26 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (6) , 945
Imatinib for control of bullous skin lesions in a child with familial mastocytosis
- 26 March 2021
- Published by Wiley in British Journal of Haematology
- Vol. 194 (6) , 945
Open AccessImatinib for control of bullous skin lesions in a child with familial mastocytosis